anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A tobacco extract, or one or more chemical compounds characteristic of a tobacco extract, is useful in the prevention or treatment of periodontal disease. The tobacco extract may be obtained from tobacco leaf, part-processed tobacco leaf or tobacco for smoking, in an aqueous solution, for example by gas or liquid phase extraction. Alternatively the compounds may be chemically synthesized. The medicinally active agent may be a chemical compound containing nitrogen, and it may be one or a mixture of alkaloids, terpenoids and carotenoids. The use of a tobacco extract or one or more chemical compounds characteristic of tobacco extract in the preparation of a medicament for the prevention or treatment of periodontal disease is also claimed. The extract may be in the form of solution, paste, jelly, gum or solid.
Transmembrane receptors in the signaling pathways of bacterial chemotaxis systems influence cell motility by forming noncovalent complexes with the cytoplasmic signaling proteins to regulate their activity. The requirements for receptor-mediated activation of CheA, the principal kinase of the Escherichia coli chemotaxis signaling pathway, can be demonstrated using self-assembled clusters of a receptor fragment (CF) derived from the cytoplasmic domain of the aspartate receptor, Tar. Histidine-tagged Tar CF can be assembled on the surface of unilamellar vesicles via a lipid containing the Nickel-nitrilotriacetic acid moiety as a headgroup. The stability of such a complex can be controlled by the properties of the template including the size and composition, which can be used, for example, to vary the 2-dimensional concentration of receptor fragments. Surface-assembled CF is also found to serve as a substrate for receptor methylation, which is catalyzed by the receptor transferase. Since neither CheA activation nor CF methylation is observed in comparable samples in the absence of vesicles, it is concluded that surface-templating generates the organization among CF subunits required for biochemical activity.
PURPOSE: A method for preparing placental extract is provided to completely prevent potential viral contamination. CONSTITUTION: A method for preparing placental extract comprises: a step of inactivating virus using surfactant and solvent; a step of inactivating virus by irradiating UV ray; and a step of removing virus using a nanofilter. The solvent is TNBP(tri-N-butyl phosphate). The intensity of the UV ray is 1,000 J/m^2-3,000 J/m^2. A method for preparing the placental extract comprises: a step of pulverizing placental tissue in an aqueous medium to prepare a placental solution; a step of separating the placental solution into an aqueous part and a solid part; a step of adding surfactant and solvent to inactivate virus; a step of removing the surfactant and solvent; a step of irradiating the placental solution with UV ray to inactivate the virus; and a step of filtering the placental solution to remove virus and bacteria. A pharmaceutical composition for preventing or treating climacteric disorders contains the placental extract and pharmaceutically acceptable carrier.
The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
The present invention relates to the technical field of gene engineering, particularly to a deinagkistrodon acutus (a five-paced pit viper) fibrinotytic(fibrinogenolytic) gene No. 8, a carrier containing the gene, a host cell for gene engineering by the carrier and a fibrinotytic(fibrinogenolytic) medicine made of the gene to resist embolism disease caused by thrombosis. Fibrinolysis factors FII are extracted from the coarse poison of a five-paced pit viper. Fibrinolysis factor FII genes are sieved and cloned. The fibrinolysis factors FII are expressed in yeast cells. The expressed products are purified, and fibrinolytic activity is measured. The present invention expressing the fibrinolysis factors by a gene engineering yeast system has the advantages of high activity, large yield, stable quality and low cost, and the present invention can become a new style potent thrombolytic drug and have great social benefits and economic benefits.
An automated external defibrillation (AED) device includes a wireless interface to exchange data with one or more other devices. The AED device collects patient data associated with a patient and identifies, based on the patient data, a heart condition associated with the patient. The AED device directs a user to apply defibrillation to the patient to address the heart condition; and forwards via the wireless interface, a notification to a dispatch device. The notification may identify, for example, a location associated with the AED device. The dispatch device may direct emergency medical assistance to the location. The AED device may collect data, used to diagnose the heart condition, from a patient device and via the wireless interface. The AED device may further forward, to a user device and via the wireless interface, instructions guiding the user to use the AED device.
FIELD: medicine. SUBSTANCE: proposed antiproteinase preparation is based on the protein inhibitor of proteinases showing polyvalence antiproteinase activity with relation to serine pancreatic and leucocyte proteinases. Preparation shows prolonged curative action and does not supress activity of serine proteinases of kallikrein-kinin and coagulating blood systems. The main components of antiproteinase preparation is ovomucoid from duck egg protein. EFFECT: enhanced quality of preparation. 2 tbl
Radiomic analysis of multiparametric magnetic resonance imaging (“MRI”) and magnetic resonance fingerprinting (“MRF”) data enhances delineation and mapping of tumor regions. Radiomic features are extracted from MRI and MRF tumor images. Distinct tumor regions, including but not limited to necrotic core, enhancing tumor, and peritumoral white matter, are segmented and mapped. Whole tumor as well as tumor region characteristics are evaluated. Tumors can also be differentiated and classified by pathology, grading, staging, and so on. Tumor infiltration into peritumoral white matter regions can also be mapped for recurrence prediction
I. Stable Angina

Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). Nicardipine hydrochloride capsules may be used alone or in combination with beta-blockers. 

II. Hypertension 

Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. Nicardipine hydrochloride capsules may be used alone or in combination with other antihypertensive drugs. In administering nicardipine it is important to be aware of the relatively large peak to trough differences in blood pressure effect (see DOSAGE AND ADMINISTRATION).
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components-the ligand and the lytic peptide-may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.
PURPOSE:To provide a solid drug containing disodium adenosine triphosphate (ATP-2Na) and a vitamin B1 derivative, having promoted drug action of ATP-2 Na and useful for the amelioration and remedy of cerebrovascular disorder, cardiac insufficiency and asthenopia. CONSTITUTION:The objective drug contains ATP-2Na and a vitamin B1 salt or a vitamin B1 derivative having vitamin B1 activity (e.g., fursultiamine or its salt). The amount of the vitamin B1 is 0.01-5pts.wt., preferably 0.1-1pt.wt. per 1pt.wt. of ATP-2Na. The decomposition of ATP-2Na can be remarkably suppressed and a drug preparation having higher stability and effectiveness can be prepared by adding >=0.1pts.wt. of a low-melting oily substance. The amount of the oily substance is preferably 0.2-1pt.wt. in the case of adding as a solid and 0.2-0.8pts.wt. as a liquid.
BACKGROUND: Cesarean scar pregnancy (CSP), a distinct form of ectopic pregnancy, presents challenges in effective management. It is categorized into three subtypes according to the location of placental implantation and the thickness of the myometrium at the uterine scar. Nevertheless, the optimal choice of treatment modalities for these subtypes remains largely unexamined.
METHODS: In this retrospective analysis, we investigated the cases of 130 patients diagnosed with CSP who underwent diverse treatment approaches, namely ultrasound-guided dilation and curettage (D&C), hysteroscopic surgery alone or in combination with laparoscopic surgery (HCoLC), or uterine artery embolization (UAE) followed by curettage. Clinical data were meticulously retrieved from medical records and follow-up data, and a comparative analysis of relevant indicators was carried out across the different CSP subtypes.
RESULTS: From January 2017 to December 2021, 35 patients underwent D&C, 85 underwent HCoLC, and 10 received UAE as a pretreatment. In the D&C group, the success rates for Type I and Type II CSP were 64.29% (18/28) and 14.28% (1/7), respectively. Significant differences were observed between the success and failure groups in terms of gestational sac size and clinical classification. Compared to Type I CSP, Type II CSP exhibited significantly longer surgical durations and higher hospitalization costs (P < 0.05). Three patients classified as Type III underwent simultaneous hysteroscopic evacuation of cesarean scar pregnancy and laparoscopic repair of the cesarean scar defect, achieving a 100% success rate in their initial treatment. HCoLC showed no significant differences in surgical duration and hospitalization costs but had higher success rates and shorter hospital stays compared to the D&C and UAE groups (P < 0.05). The UAE group had significantly longer surgical durations, higher hospitalization costs, and a higher incidence of postoperative complications (P < 0.05). However, these factors did not result in improved surgical success rates.
CONCLUSION: The classification of CSP and the measurement of gestational sac are of crucial importance in determining the most appropriate surgical intervention strategy. For patients diagnosed with Type I CSP, D&C and hysteroscopy are reliable treatment choices. In cases with larger gestational sacs or Type II CSP, hysteroscopy, either alone or in combination with laparoscopy, is regarded as a reliable and effective treatment approach. In patients with type III CSP, lesion excision with uterine repair is the recommended treatment.
PROBLEM TO BE SOLVED: To obtain an agent effective for relaxing or deshrinking the skin or subcutaneous tissue and useful for the beautifying treatment of wrinkle and crease by including a specific inhibitor. SOLUTION: A calcium channel inhibitor (e.g. verapamil and calcium complexing agent) is included in an agent composition in an amount of preferably 0.0001-10% based on the total weight of the composition. The composition may contain a medium compatible with skin and take the form of dispersed liquid, aerosol, emulsion, gel, etc. In the case of the emulsion, the ratio of the fat phase is preferably 5-80% based on the total weight and the emulsion is incorporated with a fatty substance (e.g. petrolatum and cetyl alcohol), an emulsifier, an adjuvant and an activation agent (e.g. glycolic acid and retinoic acid).
The invention discloses an external liquid medicine for skin diseases and a preparation technology thereof. The producing raw materials of the liquid medicine comprise tomato juice, bioactive active enzymes, preservatives and traditional Chinese medicine materials. The preparation method comprises the following steps: preparing mother liquid with the raw materials of the tomato juice, the bioactive mildew and the preservatives, wherein the weight proportion of the raw materials of the tomato juice to the raw materials of the bioactive mildew and the raw materials of the preservatives is 100:4:1, adding 0.8 kg of traditional Chinese medicine materials to every 4 liters of mother liquid which is made of the tomato juice, the bioactive active enzymes and the preservatives, soaking the traditional Chinese medicine material in the mother liquid to prepare the liquid medicine, and filtering the traditional Chinese medicine materials after the traditional Chinese medicine materials are soaked for 7-10 days. The bioactive active enzymes are bean curds which are fermented. The preservatives are sodium benzoate. A part of the medicine materials is prepared from 5 g of rhizoma anemarrhenae, 5 g of phellodendron, 4 g of tree peony bark, 4 g of poria cocos, 4 g of rhizoma alismatis, 3 g of Chinese yam, 3 g of cornel and 4 g of digitalis. The external liquid medicine for the skin diseases has the curative effects of clearing heat, removing toxicity and resisting allergy. The external liquid medicine is mainly used for treating the skin diseases, such as whelk, pollinosis, solar dermatitis, neurodermitis, beriberi, ringworm, empyrosis and infrared injury, and is used for expelling mosquitoes, relieving itching and the like.
In studies conducted under the auspices of the National Toxicology Program, groups of rats were fed diets containing 0, 150, 300 or 600 ppm triamterene, and groups of mice were fed diets containing 0, 100, 200 or 400 ppm triamterene. Male and female rats exposed to the highest tested concentration received triamterene at about 25 and 30 mg/kg/day, respectively. Male and female mice exposed to the highest tested concentration received triamterene at about 45 and 60 mg/kg/day, respectively.

There was an increased incidence of hepatocellular neoplasia (primarily adenomas) in male and female mice at the highest dosage level. These doses represent 7.5 times and 10 times the MRHD of 300 mg/kg (or 6 mg/kg/day based on a 50 kg patient) for male and female mice, respectively when based on body-weight and 0.7 times and 0.9 times the MRHD when based on body-surface area. Although hepatocellular neoplasia (exclusively adenomas) in the rat study was limited to triamterene-exposed males, incidence was not dose-dependent and there was no statistically significant difference from control incidence at any dose level.
The coronavirus disease 2019 (COVID-19) disease caused by the severe acute respiratory syndrome coronavirus 2 has had a widespread global impact. In addition to the main respiratory symptoms, research has found significant effects of this virus on the cardiovascular system. This article comprehensively explores the phenomenon of "long-term COVID-19" or postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection, wherein some recovered patients continue to experience long-term health issues after the resolution of acute illness. We delve into the potential reasons behind these symptoms, including increased risk of heart disease, myocardial injury, abnormal inflammatory responses, thrombosis formation, and immune system dysfunction, among others. Furthermore, this paper highlights the potential association between long-term COVID-19 and HF (heart failure), and proposes corresponding preventive strategies. To address this, we advocate for a collaborative approach involving interdisciplinary teams for treatment and management.
Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
According to DEFINITION criteria, PCI of the complex coronary bifurcation with up-front two stent techniques is associated with lower target vessel revascularisation (TVR) than Provisional Stenting. The Double-Kissing Crush stenting (DK-Crush) has been tested with the Culotte and the Classic Crush techniques in the unprotected left main disease (ULMD) and in no-ULMD setting, respectively, showing better clinical outcomes. However, due to its technical complexity and simultaneous improvement of the Classic Crush technique in the External Minicrush, the latter has become the most used technique in the clinical practice in treating complex coronary bifurcation. The DK-Crush technique has never been tested with the External Minicrush, leaving the operators to choose one or the other according to their experience and preferences. The Reverse T-stenting, And Minimal Protrusion (Reverse TAP) is an up-front 2-stent technique that treats complex coronary bifurcation. Compared to crush techniques, it does not require crushing of the side branch stent but only minimal protrusion of the side branch stent before main vessel stenting. Nowadays, studies need to compare the Reverse-TAP and the External Minicrush in treating complex coronary bifurcation, so eventually, procedural, clinical and safety differences remain unknown.
A prosthetic part (10) for use as an orthopedic implant has a base member defining an outer surface (20) for implantation adjacent a prepared bone surface (21). The outer surface (20) includes a recessed area (16) having a predetermined shape and depth. A first rigid plate (22) having this predetermined shape and having a plurality of elongated slots (26) formed therein is fixedly attached within the recessed area (16) of the base member. A second rigid plate (24) also having the same predetermined shape as the recess and also having a plurality of elongated slots (28) formed therein is attached to the first rigid plate. The elongated slots (28) of the second plate (24) are angularly offset with respect to the elongated slots (26) in the first plate to produce a controlled porosity. The thicknesses of the first and second plates are predetermined so that the outer surface (18) of the second plate is substantially continuous with the non-recessed outer surface (20) of the base member (10).
Small nucleolar RNAs (snoRNAs) were previously regarded as a class of functionally conserved housekeeping genes, primarily involved in the regulation of ribosome biogenesis by ribosomal RNA (rRNA) modification. However, some of them are involved in several biological processes via complex molecular mechanisms. DNA damage response (DDR) is a conserved mechanism for maintaining genomic stability to prevent the occurrence of various human diseases. It has recently been revealed that snoRNAs are involved in DDR at multiple levels, indicating their relevant theoretical and clinical significance in this field. The present review systematically addresses four main points, including the biosynthesis and classification of snoRNAs, the mechanisms through which snoRNAs regulate target molecules, snoRNAs in the process of DDR, and the significance of snoRNA in disease diagnosis and treatment. It focuses on the potential functions of snoRNAs in DDR to help in the discovery of the roles of snoRNAs in maintaining genome stability and pathological processes.
The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.
BACKGROUND: Hepatitis B surface antigen (HBsAg) loss is regarded as a pivotal criterion for assessing functional cure in patients diagnosed chronic hepatitis B (CHB). We conducted the research to investigate the real-world performance of HBsAg seroconversion in sustaining HBsAg loss.
METHODS: This retrospective analysis confirmed 295 patients who attained HBsAg loss through combination therapy involving nucleos(t)ide analogues (NAs) and pegylated interferon alpha (peg-IFNα). Employing Kaplan-Meier estimates method to conduct survival analysis. The forest plot was used to visualize the results of multivariate Cox regression, and selected variables were included in the nomogram.
RESULTS: HBsAg seroreversion was observed in 45 patients during follow-up periods, with a lower recurrence risk in patients with HBsAg seroconversion at the end of peg-IFNα therapy (EOT) (10.3% vs 37.3% at 96-week, P < 0.0001). Moreover, the sustainability of hepatitis B surface antibody (anti-HBs) in participants continuing therapy after HBsAg seroconversion was superior to those discontinued prematurely (72.5% vs 54.5% at 96 weeks, P = 0.012). Additionally, the former group was also relatively less likely to experience HBsAg reversion during long-term observation (8.4% vs 14.3% at 96 weeks, P = 0.280). Hepatitis B envelope antigen (HBeAg) status, anti-HBs status and consolidation treatment screened by multivariable analysis were utilized to construct a predictive model for HBsAg reversion. The concordance index(C-index = 0.77) and calibration plots indicated satisfactory discrimination and consistency of nomogram.
CONCLUSIONS: HBsAg seroconversion was beneficial for sustaining functional cure in patients treated with peg-IFNα. Continuing consolidation therapy after HBsAg seroconversion also contributed to maintain HBsAg seroconversion and improve the durability of HBsAg loss. The nomogram illustrated its efficacy as a valuable instrument in showcasing survival probability of functional cure.